Why this East Bay biotech company shed half its value

Wall Street pummeled Sangamo Therapeutics Inc., at one point halving the value of the company's stock Thursday after it reported poor results in a pioneering clinical trial.

In a first-in-the-United-States clinical trial that attempted to edit genes inside people with a deforming and muscle-weakening lysosomal storage disease, the Richmond-based company (NASDAQ: SGMO) said its experimental drug saw limited success. That led anxious investors to drive Sangamo's stock from its opening price of $12.50…

Previous Niagara Falls Memorial shifts to community health model
Next These Portland metro schools have the highest rates of unvaccinated students

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *